MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
QURE

QURE

uniQure N.V.

$50.78
-0.18
 (-0.34%)
Exchange:  NASDAQ
Market Cap:  3.522B
Shares Outstanding:  17.595M
Delayed data
Calculate QURE Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Matthew C. Kapusta
Full Time Employees:  221
Address: 
Paasheuvelweg 25
Amsterdam
NH
1105 BP
NL
Website:  https://www.uniqure.com
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/07/29 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue15,84327,11916,098
Gross Profit2,2158,79214,412
EBITDA-253,100-160,745-116,587
Operating Income-282,871-184,294-187,827
Net Income-308,478-239,556-198,971

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets831,689556,536824,908
Total Liabilities624,019563,288626,007
Total Stockholders Equity207,670-6,752198,901
Total Debt138,40966,06163,393
Cash and Cash Equivalents241,360158,93080,240

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-145,929-182,728-177,963
Capital Expenditure-7,154-3,3680
Free Cash Flow-153,083-186,096-177,963
Net Income-308,478-239,556-198,971
Net Change in Cash13,371-84,2150

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)254,386.537Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,808,836.239Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)882,063.667Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-1,226,833.663Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-172,536.330Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-598,255.042Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)16,621.548Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)524,901.311Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)221,861.957Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)567,860.873Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)4,037,821.099Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,969,009.249Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)3.860Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)9.130Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.290Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
15.843M  ?P/S
 (TTM)
: 
179.69
?Net Income
 (TTM)
: 
-308478000  ?P/E
 (TTM)
: 
-11.97
?Enterprise Value
 (TTM)
: 
3.005B  ?EV/FCF
 (TTM)
: 
-18.66
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-111.96%  ?ROIC
 (TTM)
: 
-22.48%
?Net Debt
 (TTM)
: 
59.042M  ?Debt/Equity
 (TTM)
: 
0.19
?P/B
 (TTM)
: 
9.89  ?Current Ratio
 (TTM)
: 
10.01

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about QURE valuation

Is uniQure N.V. (QURE) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for uniQure N.V. (QURE) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is QURE a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether QURE trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is QURE’s P/E ratio?

You can see QURE’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for QURE?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is QURE a good long-term investment?

Whether QURE fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

QURE

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.34
MARKETSnap

Trading Metrics:

Open: 50.72   Previous Close: 50.95
Day Low: 50.51   Day High: 51.09
Year Low: 8.73   Year High: 71.5
Price Avg 50: 44.06   Price Avg 200: 27.73
Volume: 41385   Average Volume: 1.902M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

uniQure Q2 Earnings Call Highlights
29-07-2026 13:05
uniQure Q2 Earnings Call Highlights
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
17-07-2026 15:56
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
17-07-2026 15:32
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
17-07-2026 15:26
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
25-06-2026 16:10
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
uniQure Announces Pricing of Upsized $225 Million Public Offering
23-06-2026 21:13
uniQure Announces Pricing of Upsized $225 Million Public Offering

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read